Search

Exploring T-cells in cancer

Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop

Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US

Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.

Propeller Health & BI Announce New Partnership | BI US

Propeller Health, the leading digital health solution for respiratory medicine and BI announce new partnership to help people living with COPD & asthma.

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

OFEV® (nintedanib) Now Available in the United States

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

Intensive education about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines

The findings demonstrate the benefit of clinic-level educational interventions

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

AbeXXa Biologics – Re-Imagining Cancer Immunotherapy for the Many

The Urgency for Heart Failure Research and New Treatment Options

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Our Partners: ViraTherapeutics

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

FDA Grants Priority Review for Spesolimab | BI US

Read more about Spesolimab, which has been approved by the FDA as a treatment option for generalized pustular psoriasis (GPP) flares in adults.

Bigger Role in Ensuring Food Security | Boehringer Ingelheim US

As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.

Protein Degraders: Changing the Game in Cancer Drug Discovery

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers